Memarnejadian Arash, Menbari Shahoo, Mansouri Seyed Ali, Sadeghi Leila, Vahabpour Rouhollah, Aghasadeghi Mohammad Reza, Mostafavi Ehsan, Abdi Mohammad
Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran.
Department of Pathology and Medical Laboratory Sciences, Faculty of Paramedicine, Kurdistan University of Medical Sciences, Sanandaj, Iran.
PLoS One. 2015 May 11;10(5):e0126955. doi: 10.1371/journal.pone.0126955. eCollection 2015.
The growing incidence and transmission of drug resistant HIV-1 strains due to widespread use of antiretroviral therapy (ART) can jeopardize the success of first-line ART. While there is a known moderate prevalence of transmitted drug resistance (TDR) among newly infected Iranians, no data exist about the rate of these primary resistance mutations among the ART-naïve, chronically infected individuals who are, in fact, the main candidates for ART initiation. To address this issue, we collected blood samples from 40 ART-naïve injection drug-users (IDUs) with chronic HIV-1 infection (seroconversion time ranging from 2 to 9 years) living in Sanandaj, Iran, followed by sequencing of the protease and reverse-transcriptase regions from their HIV-1 genome. Phylogenetic analyses of the sequenced regions revealed that all samples were CRF35_AD. Transmitted resistance mutations were interpreted as surveillance drug-resistant mutations (SDRMs) based on the world health organization (WHO) algorithm. The frequency of SDRMs to any class of antiretroviral drugs was 15%, which included mutations to nucleoside reverse transcriptase inhibitors (NRTIs, 10%), with M41L and M184V as the most common (5%), and non-nucleoside reverse transcriptase inhibitors (NNRTIs, 5%), with K103N as the only detected mutation (5%). Although not in the WHO SDRMs list, several minor protease inhibitor resistant mutations listed in the International Antiviral Society-USA panel were identified, of which M36I, H69K, L89M/V/I (each one 100%) and K20R/T (92.5%) can be considered as polymorphic signatures for CRF35_AD.The relatively high rate of TDR mutations in our study raises concerns about the risk of treatment failure in chronically infected IDUs of Sanandaj city. These results suggest that routine resistance testing should be considered before the therapy initiation in this area. Additional surveillance studies are required to generalize this deduction to other cities of Iran.
由于抗逆转录病毒疗法(ART)的广泛使用,耐药性HIV-1毒株的发病率和传播日益增加,这可能会危及一线ART的治疗效果。虽然已知在新感染的伊朗人中传播性耐药(TDR)的患病率中等,但对于事实上是开始ART主要候选人群的未接受过ART治疗的慢性感染个体中这些原发性耐药突变的发生率,尚无相关数据。为解决这一问题,我们从伊朗萨南达杰的40名未接受过ART治疗的慢性HIV-1感染注射吸毒者(IDU)中采集了血样(血清转化时间为2至9年),随后对其HIV-1基因组的蛋白酶和逆转录酶区域进行测序。对测序区域的系统发育分析表明,所有样本均为CRF35_AD。根据世界卫生组织(WHO)算法,将传播性耐药突变解释为监测性耐药突变(SDRM)。对任何一类抗逆转录病毒药物的SDRM频率为15%,其中包括对核苷类逆转录酶抑制剂(NRTI,10%)的突变,最常见的是M41L和M184V(5%),以及对非核苷类逆转录酶抑制剂(NNRTI,5%)的突变,唯一检测到的突变是K103N(5%)。虽然不在WHO的SDRM列表中,但在国际抗病毒协会-美国小组列出的几种次要蛋白酶抑制剂耐药突变被识别出来,其中M36I、H69K、L89M/V/I(各为100%)和K20R/T(92.5%)可被视为CRF35_AD的多态性特征。我们研究中相对较高的TDR突变率引发了对萨南达杰市慢性感染IDU治疗失败风险的担忧。这些结果表明,在该地区开始治疗前应考虑进行常规耐药检测。需要进行额外的监测研究,以将这一推断推广至伊朗的其他城市。